Fate Therapeutics, Inc. (FATE)
|52 Week Range||17.1-66.56|
|1y Target Est||-|
|DCF Unlevered||FATE DCF ->|
|DCF Levered||FATE LDCF ->|
|Debt / Equity||44.66%||Neutral|
Upgrades & Downgrades
Latest FATE news
Fate Therapeutics: Returning To The Ticker That Changed The Way I Invest
15 November 2022
Fate Therapeutics was one of my favorite investments, however, I made the haunting mistake of closing the position only to see the ticker nearly triple. This time will be different. FATE has lost roug...
Fate Therapeutics to Present at Upcoming Investor Conferences
4 November 2022
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of p...
Fate Therapeutics, Inc. (FATE) Q3 2022 Earnings Call Transcript
3 November 2022
Fate Therapeutics, Inc. (NASDAQ:FATE ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial ...
Fate Therapeutics to Participate at Upcoming September Investor Conferences
2 September 2022
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of ...
The 5 Top Stocks Cathie Wood Is Buying Now
15 August 2022
Cathie Wood's Ark Invest has performed well recently, with shares of her flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT: ARKK ), up more than 15% during the past month. The perfo...
3 Cathie Wood Stocks for the Future
14 August 2022
Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock
12 August 2022
Source: ra2 studio/Shutterstock Shares of Fate Therapeutics (NASDAQ: FATE ) stock are up 3% following a massive purchase by two of Cathie Wood's exchange-traded funds (ETFs). Fate is a clinical stage ...
ARK's Cathie Wood Dumps More Twitter Stock, Buys $20M in Fate Therapeutics Stock
12 August 2022
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm's exchange-traded funds (E...
7 Small-Cap Stocks to Buy Before the Bull Market Returns
7 August 2022
Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-te...